Anti-6X His tag monoclonal antibody, clone BE2.2.20 [FITC]

Following the ban on the use of in-feed antimicrobials, necrotic enteritis (NE) NE is the most important clostridial disease. Vaccination has been considered as a possible approach to prevent NE. Our previous study showed that a chimeric protein product consisting of antigenic epitopes of NetB, Alpha-toxin and Zinc metallopeptidase (Zmp) triggered immune response against C. perfringens. In the current study we optimized the chimeric gene and constructed a fusion protein containing NetB, Alpha-toxin and Metallopeptidase (NAM) for expressing in tobacco plant to use as an edible vaccine for immunizing the chicken against NE. Simultaneously, we expressed and purified a His-tagged recombinant version of the NAM (rNAM) expressed in E. coli BL21 for subcutaneous immunization of chickens. Immunized birds produced strong humoral immune responses against both edible plant-based and parenteral purified rNAM. The responses were determined by the mean titer of antibody in blood samples to be around 9000 and 32,000, for edible and injected rNAM, respectively. Birds immunized subcutaneously showed the most striking responses. However the edible vaccine provided a more long lasting IgY response 14 days after the third vaccination compared to the injected birds. Chickens immunized with either lyophilized leaves expressing rNAM or purified rNAM, subsequently were subjected to the challenge with a virulent C. perfringens strain using an NE disease model. Our results showed that birds immunized both parenterally and orally with recombinant chimeric vaccine were significantly protected against the severity of lesion in the intestinal tract, but the protection provided with the injectable form of the antigen was greater than that of the oral form. Further analysis is needed to check whether these strategies can be used as the potential platform for developing an efficient vaccine against NE. (C) 2020 Elsevier Ltd. All rights reserved.

Background: Human insulin like growth factor-1 (IGF1) is a hormonal peptide associated with growth and development in mammalian. It has become a particularly attractive therapeutic target because of its role in various physiological processes. IGF1 binding to its receptor IGF1R on the surface of the cell triggers a signaling cascade leading to proliferative and anti-apoptotic events. Results: We constructed an adapter of codon optimized IGF1 gene with two different linkers; rigid: EAAAK (E) and flexible: GSGSG (G), which was cloned in the plasmid pRSET-sfGFP as a fusion partner to the superfolder form of green fluorescent protein (sfGFP), resulting in the constructs pRSET-sfGFP-IGF1-(E or G). The expressed 6x His tagged sfGFP-IGF1-E protein (36 kDa) was purified from the cytoplasm of E. coli by metal affinity chromatography. Its purity was confirmed by SDS-PAGE blue staining and immunoblotting with anti-His or anti-GFP antibodies. Proper folding of sfGFP-IGF1-E was confirmed by indirect ELISA that revealed the ability of the sfGFP-IGF1-E but not the sfGFP, to bind to the immobilized IGF binding protein 3 (IGFBP3), and the ability of IGFBP3 to bind to the immobilized sfGFP-IGF1-E. Both interactions were able to be detected by anti-GFP and anti-IGFBP3, respectively. XTT test confirmed the bioactivity of sfGFP-IGF1-E after MCF-7 and HepG2 cancer cell lines treatment with increased concentrations of sfGFP-IGF1-E. Conclusions: The procedure described in this study facilitates the production of effectively sfGFP-IGF1-E fusion protein in sufficiently large amounts, which provides a promising curative compound for many disorders.